Product Description
Mechanisms of Action: TOP1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Glioblastoma
Phase 2: Gastrointestinal Cancer|Breast Cancer
Phase 1: Gastrointestinal Cancer|Esophageal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
EDOABC-4439-001 | P2 |
Completed |
Breast Cancer |
2007-06-01 |
|
CDR0000329917 | P2 |
Completed |
Breast Cancer |
2006-04-01 |
|
CDR0000339607 | P1 |
Completed |
Esophageal Cancer|Gastrointestinal Cancer |
2005-12-01 |
|
EDOAGA-6736-001 | P2 |
Completed |
Gastrointestinal Cancer |
2005-06-01 |